الفهرس 
ConclusionsOnly 14 pages are availabe for public view
 |  | from | 202 |  |  |
| | | from | 202 | | |
Abstract
Our children with MDS were older in age at presentation (compared to data from North America and European countries), showed absence of anemia in a significant proportion of our children and a lower frequency of abnormal cytogenetics in our children. Running in harmony with other pediatric studies, the IPSS was not of prognostic significance in our children in the total group and in each diagnostic subset of MDS or JMML. PBSCT proved to be superior to chemotherapy in children with early stages of MDS and those with JMML. On the other hand intensive AML-like chemotherapy was successfully able to achieve and maintain remission in a substantial group of patients diagnosed as RAEB-II. (Key Wards: Childhood MDS, JMML, stem cell transplantation, chemotherapy in myelodysplastic and myeloproliferative diseases)